Compare CYN & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYN | TVRD |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | 62 | 12 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 25.0M |
| IPO Year | 2021 | N/A |
| Metric | CYN | TVRD |
|---|---|---|
| Price | $1.20 | $2.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | ★ 222.3K | 54.3K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $368,138.00 | N/A |
| Revenue This Year | $3,359.28 | N/A |
| Revenue Next Year | $347.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.10 | $2.34 |
| 52 Week High | $17.20 | $43.65 |
| Indicator | CYN | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 29.35 |
| Support Level | N/A | N/A |
| Resistance Level | $1.76 | $4.42 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 38.89 | 6.08 |
Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.